BiotechTube
Neurophyxia

Neurophyxia

Leiden, Netherlands· Est.
neurophyxia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Neurophyxia is a private, clinical-stage Dutch biotech advancing 2-iminobiotin (2-IB), a novel neuroprotectant, into a Phase IIb/III trial for cerebral hypoxia-ischemia following stroke, with secondary indications in cardiac arrest and birth asphyxia. Founded on academic research, the company is managed by a lean team of founders and specialized consultants with deep pharmaceutical development experience. As a pre-revenue entity, its near-term value inflection hinges on the success of its pivotal clinical program for a significant unmet medical need in neuroprotection.

NeurologyCardiologyNeonatology

Technology Platform

Development of selective neuronal nitric oxide synthase (nNOS) inhibitors, specifically 2-iminobiotin (2-IB), to prevent reperfusion injury and cell death following cerebral hypoxia-ischemia.

Funding History

2
Total raised:$3M
Grant$500K
Seed$2.5M

Opportunities

Positive Phase IIb/III data in stroke would validate the nNOS inhibition approach and position Neurophyxia for a high-value partnership or acquisition, given the massive unmet need.
The drug's potential application in neonatal HIE and cardiac arrest offers additional, high-need pathways for expansion and possible orphan drug designations.

Risk Factors

The lead program faces high risk of clinical failure, a common outcome in neuroprotection trials.
The company's virtual model and pre-revenue status create significant financial dependency on raising capital to fund expensive late-stage trials.
Competition, though historically ineffective, remains from other entities pursuing neuroprotective strategies.

Competitive Landscape

The neuroprotection field is challenging with few approved drugs, but includes companies exploring various mechanisms like free radical scavengers, anti-apoptotics, and hypothermia devices. Neurophyxia's differentiation lies in the selective targeting of nNOS. Its most direct competitors would be other biotechs developing pharmacological agents for adjunctive use post-reperfusion in stroke or for neonatal HIE.

More companies in Small Molecule Drugs →More companies in Netherlands →